8:30 am Morning Coffee & Networking

Chair Day Two: Paola Grandi

Advancing the Delivery of Oncolytic Virotherapies – Intertumoral vs Intravenous Administration

9:00 am Intravenous Administration of an Oncolytic Vesicular Stomatitis Virus: Clinical Experience to Date


  • Voyager V1 has been administered intravenously to over 100 cancer patients in clinical trials
  • Compelling evidence of single agent activity after a single infusion will be presented

9:30 am Clinical Biomarker Studies with an Enhanced Potency


  • Oncolytic HSV Expressing an Anti-CTLA-4 Antibody as a
  • Single Agent and Combined with Nivolumab in Patients with
  • Advanced Solid Tumors Indicates Potent Immune Activation

10:00 am Allogeneic Stem Cell-Based Platforms to Potentiate and Deliver Oncolytic Virus Therapies

  • Boris Minev President, Medical & Scientific Affairs, Calidi Biotherapeutics


  • Shortcomings of unprotected oncolytic virus therapies
  • Advantages of Calidi’s stem cell-based platforms for potentiation of oncolytic virotherapies – preclinical data
  • Calidi’s clinical programs

10:30 am Clinical Trials of Oncolytic Virotherapy for Brain Tumors

  • Antonio Chiocca Chairman, Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School


  • Define how OV’s change the tumor microenvironment
  • Review current status of clinical trials in brain tumors
  • Focus on future avenues of research

11:00 am Morning Break & Refreshments

Navigating the Landscape – Investment, Regulatory Guidelines & Partnering

12:00 pm Panel Discussion: Navigating the Field of Oncolytic Virus Partnering & Investment

  • Natalia Ulyanova Director Oncology Business Development, Search & Evaluation, Astellas
  • Enoch Yue Associate Director, Business Development Oncology Search & Evaluation, Bristol Myers Squibb
  • Karen Ann Cherkis Senior Director Search & Evaluation, Bristol Myers Squibb
  • Patrik Erlmann Head of Research Beyond Borders, Boehringer Ingelhiem


Understand the Necessary Parameters for An Attractive Potential New Partner in The Field of Oncolytic Viruses with Examples from The Field

  • What are the fundamental assets a biotech must have when approaching large pharma for a potential licensing agreement or acquisition proposition?
  • Acquisition vs Licensing: Is there a preferential route for large pharma?
  • Where will future innovation come from within the field of oncolytic viruses?

12:30 pm Lunch Break & Networking

Insights from Within the Clinic: Demonstrating the New Generation of Oncolytic Viruses

2:00 pm Clinical Update & Lessons Learned with Talimogene Laherparepvec in Solid Tumor Oncology

  • Austin Nuschke Senior Medical Scientist, Solid Tumor Oncology, Amgen

2:30 pm Rationale Design of Phase 1 Trial Combining Oncolytic Virotherapy with CAR-T Cells

  • Neil Sheppard Director & Head T Cell Engineering Lab, University of Pennsylvania Center for Cellular Immunotherapies


  • CAR-T therapy of solid tumors is limited by tumor microenvironments that exclude and suppress T cells such as huCART-meso cells targeting mesothelin
  • VCN-01, a PH20 hyaluronidase-armed Oncolytic Virus degrades tumor extracellular matrix, reprograms the tumor microenvironment, and draws T cells into tumor lesions
  • We designed a combination trial NCT05057715 to establish the safety, feasibility, and preliminary efficacy of a combination of huCART-meso cells and VCN-01 in patients with pancreatic or ovarian cancer

3:00 pm Oncolytic Viral Immunotherapy For Hard-To-Treat Solid Tumors

  • Paul Peter Tak President & Chief Executive Officer, Candel Therapeutics


  • Introduction to oncolytic viral immunotherapy as a new approach to induce a specific immune response against the injected solid tumor and uninjected distant metastases
  • Clinical and immunological data showing the effects of experimental treatment with CAN-2409 in combination with immune checkpoint inhibitors (ICI) in patients with stage III/IV NSCLC who had an inadequate response to ICI as well treatment with CAN-2409 in combination with nivolumab and first-line standard of care in patients with high-grade glioma
  • Clinical and immunological data showing the effects of CAN-3110 in patients with recurrent high-grade glioma

3:30 pm End of 7th Oncolytic Virotherapy Summit 2022